<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03408262</url>
  </required_header>
  <id_info>
    <org_study_id>Ad4HIV</org_study_id>
    <nct_id>NCT03408262</nct_id>
  </id_info>
  <brief_title>Clinical Trial of HIV Vaccine Combinations in Healthy Men and Women</brief_title>
  <acronym>Ad4HIV</acronym>
  <official_title>A Phase I Single-Blind Randomised Trial Investigating Immunisation Strategies Using Ad4-EnvCN54, MVA-CN54 and CN54gp140/MPLA Combinations in Order to Maximise Antibody Responses to Human Immunodeficiency Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imperial College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised two-part Phase I study which will explore the impact of different
      boosting options (MVA-CN54 and recombinant CN54gp140 protein) for oral Adenovirus serotype 4
      vector prime expressing HIV-1 CN54 envelope (Ad4-EnvCN54) designed to optimize systemic and
      mucosal antibody responses.

      Part 1 is exploratory and designed to select conditions capable of promoting enhanced
      systemic and mucosal B cell responses in a limited number of participants. Part 2 is
      dependent upon Part 1 and is designed to study groups selected on performance in part 1 in an
      expanded number of subjects. Data from both stages will be combined for safety and
      immunological analyses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 6, 2017</start_date>
  <completion_date type="Anticipated">December 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mucosal antigen-specific antibodies measured by binding ELISA</measure>
    <time_frame>At two weeks after the final immunisation</time_frame>
    <description>Frequency of mucosal binding antibodies to HIV CN54gp140 antigen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to twenty-four weeks after the final immunisation</time_frame>
    <description>Frequency of adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum and mucosal antigen-specific antibodies measured by binding ELISA</measure>
    <time_frame>Up to twenty-four weeks after the final immunisation</time_frame>
    <description>Frequency of serum and mucosal binding antibodies to HIV CN54gp140 antigen</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Month 0: oral placebo Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Month 0: Ad4-EnvCN54 Month 3: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: oral placebo + I.M. CN54gp140/MPLA + I.M. MVA-CN54</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Month 0: Ad4-EnvCN54 Month 3: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54 Month 6: Ad4-EnvCN54 + I.M. CN54gp140/MPLA + I.M. MVA-CN54</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad4-EnvCN54</intervention_name>
    <description>Live, replication-competent adenovirus 4 vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-CN54</intervention_name>
    <description>Live, non-replicating modified vaccinia Ankara vector, engineered to express the envelope glycoprotein of HIV-1 isolate 97CN54</description>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CN54gp140/MPLA</intervention_name>
    <description>Recombinant glycoprotein of HIV-1 isolate 97CN54, with liposomal monophosphoryl lipid A adjuvant</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_label>Group F</arm_group_label>
    <arm_group_label>Group G</arm_group_label>
    <arm_group_label>Group H</arm_group_label>
    <other_name>CN54-M</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men and women aged between 18 and 50 years on the day of screening

          2. BMI between 18-30

          3. Seronegative for Adenovirus 4 serum neutralising antibodies

          4. Available for follow-up for the duration of the study

          5. Willing and able to give written informed consent

          6. At low risk of HIV infection and willing to remain so for the duration of the study
             defined as:

               -  no history of injecting drug use in the previous ten years

               -  no gonorrhoea or syphilis in the last six months

               -  no high risk partner (e.g. injecting drug use, HIV positive partner) either
                  currently or within the past six months

               -  no unprotected anal or vaginal intercourse in the last six months, outside a
                  relationship with a regular partner known to be HIV negative

          7. Willing to undergo HIV testing

          8. Willing to undergo a STI screen for chlamydia, gonorrhoea and syphilis

          9. Must agree to require male sexual partner to use condoms, from at least 14 days before
             the first vaccination until at least 4 months after the last

         10. If heterosexually active female capable of becoming pregnant, must (in addition to
             requiring male partner to use condoms) agree to use hormonal contraception, or to
             complete abstinence, from at least 30 days before the first vaccination until at least
             4 months after the last. [Note: Acceptable hormonal contraception is combined
             (estrogen and progestogen containing) or progestogen-only hormonal contraception
             associated with inhibition of ovulation. Complete abstinence can be used, when in line
             with the preferred and usual lifestyle of the subject. Periodic abstinence (calendar,
             symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides
             only, lactational amenorrhoea method, and IUD/IUS are not acceptable methods of
             contraception.]

         11. If sexually active male, must agree to use condoms from the day of first vaccination
             until at least 4 months after the last. [Note: Additional use of an effective method
             of contraception is recommended for any non-pregnant female partner over the same
             period.]

         12. Agree to abstain from donating blood, eggs or sperm from the day of first vaccination
             until at least 3 months after the end of their participation in the trial

         13. Registered with a GP for at least the past month

         14. Entered and clearance obtained from The Overvolunteering Prevention System (TOPS)
             database

        Exclusion Criteria:

          1. Are pregnant or breast feeding, or living with anyone under the age of 5 years old or
             over 75 years old

          2. Have close contact with an immunocompromised individual thought to be at clinical risk
             from Adenovirus infection

          3. Clinically relevant abnormality on history or examination including:

               1. Liver disease with inadequate hepatic function

               2. Any skin condition which may interfere with the trial assessment of the injection
                  sites

               3. Haematological, metabolic, gastrointestinal or cardio-pulmonary disorders

               4. Uncontrolled infection; autoimmune disease, immunodeficiency

          4. Known hypersensitivity to any component of the vaccine formulations used in this
             trial, or have severe or multiple allergies to drugs or pharmaceutical agents

          5. History of severe local or general reaction to vaccination defined as

               -  Local: extensive, indurated redness and swelling involving most of the
                  antero-lateral thigh or the arm, not resolving within 72 hours

               -  General: fever ≥39.5oC within 48 hours; anaphylaxis; bronchospasm; laryngeal
                  oedema; collapse; convulsions or encephalopathy within 72 hours

          6. Receipt of live attenuated vaccine within 60 days or other vaccine within 30 days of
             enrolment

          7. Receipt of an experimental vaccines containing HIV antigens, Ad4 and MVA-C products at
             any time in the past

          8. Receipt of blood products or immunoglobin within 4 months of screening, or drugs that
             suppress the immune system, such as steroids (including inhaled steroids, excluding
             topical steroids unless applied to the upper arm), in the preceding 3 months

          9. Participating in another trial of a medicinal product, completed less than 30 days
             prior to enrolment

         10. HIV 1 or 2 positive or indeterminate on screening

         11. Positive for antibodies to hepatitis B surface antigen, hepatitis C antibody or
             serology indicating active syphilis requiring treatment

         12. Clinically significant positive reaction in antinuclear antibody screen or clinically
             significant immunoglobulin (IgA, IgG or IgM) values

         13. Grade 1 or above clinically significant routine laboratory parameters

         14. Unable to read and/or speak English to a fluency level adequate for the full
             comprehension of procedures required in participation and consent

         15. Women with a history of toxic shock syndrome

         16. Women using an intrauterine device for contraception (as incompatible with softcup
             sampling)

         17. Any other significant disease, disorder or finding which may significantly increase
             the risk to the volunteer because of participation in the study, affect the ability of
             the volunteer to participate in the study or impair interpretation of the study data

         18. Unlikely to comply with protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Lewis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imperial College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tom Cole, PhD</last_name>
    <phone>02033136198</phone>
    <email>t.cole@imperial.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David Lewis, MD</last_name>
    <phone>02033136195</phone>
    <email>d.lewis@imperial.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>NIHR Imperial Clinical Research Facility</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allan Listanco</last_name>
      <email>allan.listanco@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 5, 2018</study_first_submitted>
  <study_first_submitted_qc>January 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 16, 2018</last_update_submitted>
  <last_update_submitted_qc>January 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

